LLY Eli Lilly and Company
Healthcare$1065.00+2.24%ClosedMarket Cap: $1.00T
As of 2026-05-25
Valuation
P/E (TTM)
43.01
PEG
0.45
P/B
30.54
P/S
13.88
EV/EBITDA
31.42
DCF Value
$534.09
FCF Yield
1.4%
Div Yield
0.6%
Margins & Returns
Gross Margin
83.5%
Operating Margin
45.9%
Net Margin
35.0%
ROE
101.3%
ROA
21.7%
ROIC
32.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $19.80B | 81.9% | $8.85B | $7.40B | $— | $1.73 |
| Q4 null | $19.29B | 85.1% | $8.78B | $6.64B | $— | $1.50 |
| FY null | $65.18B | 83.8% | $29.70B | $20.64B | $— | $6.00 |
| Q3 null | $17.60B | 82.9% | $8.39B | $5.58B | $— | $1.50 |
| Q2 null | $15.56B | 84.3% | $7.13B | $5.66B | $— | $1.50 |
| Q1 null | $12.73B | 82.5% | $5.41B | $2.76B | $— | $1.50 |
| Q4 null | $13.53B | 82.2% | $5.80B | $4.41B | $— | $1.30 |
| FY null | $45.04B | 81.3% | $17.50B | $10.59B | $— | $5.20 |
| Q3 null | $11.44B | 81.0% | $4.55B | $970.3M | $— | $1.30 |
| Q2 null | $11.30B | 80.8% | $4.42B | $2.97B | $— | $1.30 |
| Q1 null | $8.77B | 80.9% | $2.74B | $2.24B | $— | $1.30 |
| Q4 2023 | $9.35B | 80.9% | $3.19B | $2.19B | $2.42 | $1.13 |